Research
Hormonal
Obesity is associated with reduced striatal D2 receptor availability, which may drive compulsive food seeking and resistance to punishment, creating a feedback loop of overeating.
Obesity often involves a biological reduction in dopamine receptors, making food rewards feel less satisfying and requiring more food to feel good. This is a biological adaptation, not just a character flaw. Reducing exposure to hyper-palatable foods can help reset receptor sensitivity over time.
GoodQualifiesHIGH confidence
A central observation is that, compared with normal weight controls, overweight and obese humans show reduced striatal D2R availability... and individuals with the Taq1A A1 allele, which is associated with reduced D2R expression, are more likely to be obese.
Why this rating
Strong human neuroimaging data and rodent models cited.
Source
Homeostasis Meets Motivation in the Battle to Control Food Intake
Carrie R. Ferrario et al. · Journal of Neuroscience · 2016
DOI 10.1523/jneurosci.2338-16.2016
narrative_reviewCited 214×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Dysregulation of homeostatic signals (specifically insulin resistance in the VTA) disrupts the inhibition of dopamine neurons, leading to unchecked motivation for food cues and contributing to obesity.Good
- Short-term exposure to palatable food can permanently alter brain wiring (synaptic density) to increase future food seeking, a process that can be reversed by insulin signaling.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →